Gilles Gallant

Company: Daiichi Sankyo

Job title: Senior Vice President, Global Head of Oncology Development, Oncology R&D

Seminars:

Providing an Update on the Development of Patritumab Deruxtecan (HER3-DXd; U3-1402) A HER3- Directed DXd Antibody-Drug Conjugate (ADC) 9:30 am

Assess the mechanism of action and preclinical profile of HER3-DXd Examine the clinical development of HER3-DXd in non-small cell lung cancer (NSCLC) Discuss the future development of HER3-DXdRead more

day: Day Two